retatrutide weight loss retatrutide clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide for weight loss: Study

It creates a significant caloric deficit and improves glycemic control, leading to substantial weight loss

Saxenda (liraglutide) a once-daily GLP-1 injection FDA-approved for chronic weight management in adults and adolescents aged 12 and older

A 32-year-old non-diabetic woman with obesity and NAFLD saw minimal progress with semaglutide

For any site using an 8 mm needle: always use a 45-degree angle with a skin pinch to avoid intramuscular injection

Any deviation from licensed dosing regimens should only occur under close medical supervision, as the risk-benefit profile at sub-therapeutic doses remains poorly characterised

Older weight loss medications like phentermine and orlistat achieve modest results (5 to 10% weight loss typically) with significant side effect profiles